ARCA biopharma‘s IND application to study Gencaro for atrial fibrillation (AF) has been accepted by the FDA and is now active. ARCA plans to evaluate Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for AF in the Phase IIb/III GENETIC-AF clinical trial, which is expected to begin enrolling patients in 1Q14. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it potential to be ...